Epigenetic regulation espeically histone modifications in breast cancer: A viable and emerging targeted therapeutic strategy.

IF 3.2 3区医学 Q2 ONCOLOGY

Journal of Cancer Pub Date : 2025-09-22 eCollection Date: 2025-01-01 DOI:10.7150/jca.119306

Yibing Zhou, Haotian Liu, Weimin Hong, Haotian Su, Yuxiao Mu, Yijie Cheng, Chaoshen Wu, Xuli Meng, Da Qian

{"title":"Epigenetic regulation espeically histone modifications in breast cancer: A viable and emerging targeted therapeutic strategy.","authors":"Yibing Zhou, Haotian Liu, Weimin Hong, Haotian Su, Yuxiao Mu, Yijie Cheng, Chaoshen Wu, Xuli Meng, Da Qian","doi":"10.7150/jca.119306","DOIUrl":null,"url":null,"abstract":"<p><p>Epigenetic regulation, encompassing DNA methylation, histone modifications, and non-coding RNA activities, is a crucial mechanism through which gene expression is modified without corresponding changes in genomic DNA sequences. Dysregulation of these mechanisms can lead to histone and DNA modifications that either suppress or enhance the expression of disease progression-related genes. Among these regulatory processes, histone modifications are particularly significant, as they contribute to genomic stability, DNA repair, and chromatin dynamics, all of which influence breast cancer initiation and progression. This review offers a detailed analysis of the current state of research centered on epigenetic regulatory factors, with a particular focus on the role that histone modifications play in the treatment of breast cancer. It also examines the interplay between epigenetic modifications and the effectiveness of radiotherapy and chemotherapy when treating breast cancer. Lastly, this article explores the potential of epigenetic regulatory factors as viable targets for the future design of new anticancer therapies.</p>","PeriodicalId":15183,"journal":{"name":"Journal of Cancer","volume":"16 13","pages":"4037-4046"},"PeriodicalIF":3.2000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491166/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/jca.119306","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Epigenetic regulation, encompassing DNA methylation, histone modifications, and non-coding RNA activities, is a crucial mechanism through which gene expression is modified without corresponding changes in genomic DNA sequences. Dysregulation of these mechanisms can lead to histone and DNA modifications that either suppress or enhance the expression of disease progression-related genes. Among these regulatory processes, histone modifications are particularly significant, as they contribute to genomic stability, DNA repair, and chromatin dynamics, all of which influence breast cancer initiation and progression. This review offers a detailed analysis of the current state of research centered on epigenetic regulatory factors, with a particular focus on the role that histone modifications play in the treatment of breast cancer. It also examines the interplay between epigenetic modifications and the effectiveness of radiotherapy and chemotherapy when treating breast cancer. Lastly, this article explores the potential of epigenetic regulatory factors as viable targets for the future design of new anticancer therapies.

Abstract Image

查看原文本刊更多论文

表观遗传调控，特别是组蛋白修饰在乳腺癌：一个可行的和新兴的靶向治疗策略。

表观遗传调控包括DNA甲基化、组蛋白修饰和非编码RNA活性，是基因表达被修饰而不改变基因组DNA序列的关键机制。这些机制的失调可导致组蛋白和DNA修饰，从而抑制或增强疾病进展相关基因的表达。在这些调节过程中，组蛋白修饰尤其重要，因为它们有助于基因组稳定性、DNA修复和染色质动力学，所有这些都影响乳腺癌的发生和进展。这篇综述提供了以表观遗传调控因子为中心的研究现状的详细分析，特别关注组蛋白修饰在乳腺癌治疗中的作用。它还检查了在治疗乳腺癌时表观遗传修饰与放疗和化疗的有效性之间的相互作用。最后，本文探讨了表观遗传调控因子作为未来设计新的抗癌疗法的可行靶点的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cancer ONCOLOGY-

CiteScore

8.10

自引率

2.60%

发文量

333

审稿时长

12 weeks

期刊介绍： Journal of Cancer is an open access, peer-reviewed journal with broad scope covering all areas of cancer research, especially novel concepts, new methods, new regimens, new therapeutic agents, and alternative approaches for early detection and intervention of cancer. The Journal is supported by an international editorial board consisting of a distinguished team of cancer researchers. Journal of Cancer aims at rapid publication of high quality results in cancer research while maintaining rigorous peer-review process.